First Patient Enrolled in Evommune’s Phase 2b Trial of an MRGPRX2 Antagonist in CSU
The first patient has been enrolled in a global Phase 2b trial of Evommune, Inc.’s EVO756, a small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2), in adults with moderate-to-severe chronic spontaneous urticaria (CSU).